Dr Guy Chamberland explains how Tetra Bio-Pharma is taking a pharmaceutical pathway to discovering and developing cannabinoid-derived products.
In an industry that could aptly be described as last year’s biggest newsmaker, it seems that Tetra Bio-Pharma has become inextricably linked to all things cannabis. The irony lies in the fact that Tetra is not a cannabis company. They don’t grow it, sell it, cultivate it or promote it. What they do, and do quite well at that, is investigate hundreds of cannabinoid molecules to see what derivatives can be unleashed and turned into evidence-based medicines that address unmet medical needs.
Tetra Bio-Pharma, headquartered in Montréal, Canada, is already considered a global biopharmaceutical leader in cannabinoid-based drug discovery and development. The company becomes more visible by the day, capturing the attention of investors and analysts who see their accelerated regulatory achievements, clinical programmes and cost management as nothing less than
... read more at: https://www.healtheuropa.eu/cannabinoid-derived-products/90245/